BCRX

BioCryst Pharmaceuticals, Inc. (BCRX) | Rumor.io

BioCryst Pharmaceuticals

BCRX

Attention (50-day avg)0%

Attention rank (50-day avg)#720

Bullish sentiment (50-day avg)62%

Price to earnings ratio7.05

Market capitalization2.2B

Earnings per share-1.4

Dividend yield (TTM)—

Revenue (annual)874.8M

Net income (annual)263.9M

Social

What share of all stock conversation is about BCRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% +0	0.01% +0	0% 0

Sep 29

BioCryst Pharmaceuticals, Inc. (BCRX) may be preparing for a BLA submission and commercial-scale production of navenibart.
A new SVP Manufacturing position was created, and a VP, Global Regulatory Affairs position was posted in 2025, which may be related to the BLA submission.
The company's future pipeline may contain licensed or acquired assets, and management is working with partnering companies to achieve this.

Generated by AI

Sentiment

Of the messages about BCRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	14.71% -68.63	67.16% +24.31	69.26% +7.33	72.88% -6.14
Bearish	85.29% +68.63	32.84% -24.31	30.74% -7.33	27.12% +6.14

Bullish· Sep 10

$BCRX has a strong financial foundation, generating over half a billion in revenue and offering a "no brainer" buying opportunity.
Despite execution risks and uncertainty, $BCRX has a potential bull case of growing market share and reaching $1B in revenue.
$BCRX is undervalued at current prices, making it an attractive buy opportunity with a potential market capitalization of $2B.

Bearish· Sep 29

The company's management is seen as incompetent, with one post stating that they "deserve to die" due to their poor leadership.
The stock's performance is expected to continue to decline, with one post suggesting it is "ready to bottom out for the 100th time."
The company's financials are a major concern, with one post highlighting the high operating costs and debt, which is seen as a "killer" for the company's future.

Generated by AI

Topics

Of the messages about BCRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	82.76%	58.38%
Technical Analysis	0%	0%	8.89%	14.01%
Macro	0%	0%	0.73%	5.73%
Analysts	0%	0%	7.26%	14.08%
Earnings	0%	0%	0.18%	7.29%
Controversies	0%	0%	0.18%	0.5%

Earnings· Aug 4

BioCryst Pharmaceuticals reported Q2 2025 earnings, with revenue of $163.35 million, beating the estimate of $149.74 million.
The company's operating profit was $29.8 million, a 239% year-over-year increase, and non-GAAP operating profit was $57.0 million, a 160% year-over-year increase.
BioCryst's CEO stated that the financial performance was the best in the company's history, driven by revenue growth and strong operating profit, and the company plans to retire all remaining term debt after selling its European ORLADEYO business.

Analysts· Aug 5

BioCryst Pharmaceuticals ($BCRX) beat revenue and EPS estimates and raised FY22 guidance to $255-$265m.
The company has a high short interest of 30%, which may be a reason for analyst downgrades, and analysts have clients with opposing interests.
Analysts have provided mixed ratings for BioCryst Pharmaceuticals, with downgrades from Evercore ISI and Oppenheimer Holdings, but a raised price target from Barclays PLC.

Announcements· Mar 26

BioCryst Pharmaceuticals, Inc. ($BCRX) has been involved in several acquisitions, but its future growth prospects are uncertain.
Global copper shortages are expected to reach 9-10M tons by 2035, driven by increasing demand from AI servers, EVs, and renewable grids.
Mining exploration companies like $NRED are crucial for identifying new copper deposits, which will be essential for meeting the growing demand for this critical metal.

Technical Analysis· Apr 8

$BCRX stock is above 18.5 resistance and has a high volume breakout, potentially leading to a continuation move towards $20.
The stock has a volume shelf from 11.75-12.25, which is currently being held, and a double bottom formation at $11.
A trade below $10.7 would be bearish, and the stock has a positive long-term trend with a neutral short-term trend.

Generated by AI

Community

Of the messages about BCRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.19%	58.79%	83.92%	81.54%
Newcomers	14.81%	41.21%	16.08%	18.46%

Regulars· Sep 29

New job postings for a VP, Global Regulatory Affairs and an SVP Manufacturing position, suggesting preparations for the BLA and commercial-scale production of navenibart, respectively.
The company is working on early-phase regulatory projects, implying additional pipeline opportunities beyond navenibart, and collaborating with partnering companies.
The regulars are discussing the stock's potential for a turnaround, with some expressing optimism about AI buying the stock and others citing the company's poor management and low market capitalization.

Newcomers· Sep 10

The newcomer is concerned about the potential threat of Nav for BioCryst Pharmaceuticals ($BCRX) and its impact on the company's future.
The newcomer believes that BioCryst Pharmaceuticals ($BCRX) has a strong potential for growth, citing the company's revenue projections and the market's current pricing.
The newcomer sees the current market price of BioCryst Pharmaceuticals ($BCRX) as a buying opportunity, with some even suggesting a "no brainer" investment.

Generated by AI

BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said

11d agoYahoo Finance

BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs

On August 28, 2026, CNBC reported that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), now consistently profitable on the strength of its hereditary angioedema drug “Orladeyo,” is looking to acquire more rare disease treatments, according to CEO Charlie Gayer. Gayer, who took the role in January, said the company expects to keep growing profits every year and does […]

12d agoYahoo Finance

BioCryst at Morgan Stanley conference: pivots to external growth

14d agoInvesting.com

BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story

BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent trading left the share price at US$8.12, with the stock down over the past week and month but modestly higher year to date. Recent trading tells a mixed story for BioCryst Pharmaceuticals, with the share price falling 18.47% over the past week and 16.63% over the past month, yet still showing an 8.27% year to date share price return and a 5.45% one year total shareholder return. This suggests that short term momentum is...

15d agoYahoo! Finance Canada

BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX)

18d agoSeeking Alpha

Also Discussed

Investors talking about BCRX also mention

#	Name	Attention
1	GRTS - Gritstone bio, Inc.	——
2	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0
3	ONCT - Oncternal Therapeutics, Inc.	——
4	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
5	TG Therapeutics Inc.TGTX	0.01%+0
6	KALV - KalVista Pharmaceuticals, Inc.	——
7	MYOV - Myovant Sciences Ltd.	——
8	Pharvaris N.V. Ordinary SharesPHVS	0%0
9	VBIV - VBI Vaccines Inc.	——
10	PRVB - Provention Bio, Inc.	——

BioCryst Pharmaceuticals, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE). Its commercial portfolio is centered on ORLADEYO, an oral therapy used to help prevent HAE attacks, alongside RAPIVAB, an injectable antiviral medicine used in the treatment of influenza in the United States. The company also supports a broader rare-disease pipeline built around oral small-molecule and protein-based therapeutics designed to address difficult-to-treat conditions. BioCryst Pharmaceuticals serves patients, physicians, and healthcare systems through specialty pharmaceutical products aimed at chronic disease management and acute treatment needs. Headquartered in Durham, North Carolina, BioCryst Pharmaceuticals plays a focused role in the rare-disease market by combining commercial medicines with targeted drug development expertise.

Website

Location

4505 Emperor Boulevard

Durham, NC, 27703

United States

Social

What share of all stock conversation is about BCRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% +0	0.01% +0	0% 0

Sep 29

BioCryst Pharmaceuticals, Inc. (BCRX) may be preparing for a BLA submission and commercial-scale production of navenibart.
A new SVP Manufacturing position was created, and a VP, Global Regulatory Affairs position was posted in 2025, which may be related to the BLA submission.
The company's future pipeline may contain licensed or acquired assets, and management is working with partnering companies to achieve this.

Generated by AI

Sentiment

Of the messages about BCRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	14.71% -68.63	67.16% +24.31	69.26% +7.33	72.88% -6.14
Bearish	85.29% +68.63	32.84% -24.31	30.74% -7.33	27.12% +6.14

Bullish· Sep 10

$BCRX has a strong financial foundation, generating over half a billion in revenue and offering a "no brainer" buying opportunity.
Despite execution risks and uncertainty, $BCRX has a potential bull case of growing market share and reaching $1B in revenue.
$BCRX is undervalued at current prices, making it an attractive buy opportunity with a potential market capitalization of $2B.

Bearish· Sep 29

The company's management is seen as incompetent, with one post stating that they "deserve to die" due to their poor leadership.
The stock's performance is expected to continue to decline, with one post suggesting it is "ready to bottom out for the 100th time."
The company's financials are a major concern, with one post highlighting the high operating costs and debt, which is seen as a "killer" for the company's future.

Generated by AI

Topics

Of the messages about BCRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	82.76%	58.38%
Technical Analysis	0%	0%	8.89%	14.01%
Macro	0%	0%	0.73%	5.73%
Analysts	0%	0%	7.26%	14.08%
Earnings	0%	0%	0.18%	7.29%
Controversies	0%	0%	0.18%	0.5%

Earnings· Aug 4

BioCryst Pharmaceuticals reported Q2 2025 earnings, with revenue of $163.35 million, beating the estimate of $149.74 million.
The company's operating profit was $29.8 million, a 239% year-over-year increase, and non-GAAP operating profit was $57.0 million, a 160% year-over-year increase.
BioCryst's CEO stated that the financial performance was the best in the company's history, driven by revenue growth and strong operating profit, and the company plans to retire all remaining term debt after selling its European ORLADEYO business.

Analysts· Aug 5

BioCryst Pharmaceuticals ($BCRX) beat revenue and EPS estimates and raised FY22 guidance to $255-$265m.
The company has a high short interest of 30%, which may be a reason for analyst downgrades, and analysts have clients with opposing interests.
Analysts have provided mixed ratings for BioCryst Pharmaceuticals, with downgrades from Evercore ISI and Oppenheimer Holdings, but a raised price target from Barclays PLC.

Announcements· Mar 26

BioCryst Pharmaceuticals, Inc. ($BCRX) has been involved in several acquisitions, but its future growth prospects are uncertain.
Global copper shortages are expected to reach 9-10M tons by 2035, driven by increasing demand from AI servers, EVs, and renewable grids.
Mining exploration companies like $NRED are crucial for identifying new copper deposits, which will be essential for meeting the growing demand for this critical metal.

Technical Analysis· Apr 8

$BCRX stock is above 18.5 resistance and has a high volume breakout, potentially leading to a continuation move towards $20.
The stock has a volume shelf from 11.75-12.25, which is currently being held, and a double bottom formation at $11.
A trade below $10.7 would be bearish, and the stock has a positive long-term trend with a neutral short-term trend.

Generated by AI

Community

Of the messages about BCRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.19%	58.79%	83.92%	81.54%
Newcomers	14.81%	41.21%	16.08%	18.46%

Regulars· Sep 29

New job postings for a VP, Global Regulatory Affairs and an SVP Manufacturing position, suggesting preparations for the BLA and commercial-scale production of navenibart, respectively.
The company is working on early-phase regulatory projects, implying additional pipeline opportunities beyond navenibart, and collaborating with partnering companies.
The regulars are discussing the stock's potential for a turnaround, with some expressing optimism about AI buying the stock and others citing the company's poor management and low market capitalization.

Newcomers· Sep 10

The newcomer is concerned about the potential threat of Nav for BioCryst Pharmaceuticals ($BCRX) and its impact on the company's future.
The newcomer believes that BioCryst Pharmaceuticals ($BCRX) has a strong potential for growth, citing the company's revenue projections and the market's current pricing.
The newcomer sees the current market price of BioCryst Pharmaceuticals ($BCRX) as a buying opportunity, with some even suggesting a "no brainer" investment.

Generated by AI

BioCryst Pharmaceuticals

Social

Sep 29

Bullish· Sep 10

Bearish· Sep 29

Earnings· Aug 4

Analysts· Aug 5

Announcements· Mar 26

Technical Analysis· Apr 8

Regulars· Sep 29

Newcomers· Sep 10

Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?

BioCryst Eyes $1B Rare-Disease Future Through External Innovation

BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs

BioCryst at Morgan Stanley conference: pivots to external growth

BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story

BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX)

Also Discussed

BioCryst Pharmaceuticals, Inc.

Company Information

Location

Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?

BioCryst Eyes $1B Rare-Disease Future Through External Innovation

BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs

BioCryst at Morgan Stanley conference: pivots to external growth

BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story

BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX)

Also Discussed

Social

Sep 29

Bullish· Sep 10

Bearish· Sep 29

Earnings· Aug 4

Analysts· Aug 5

Announcements· Mar 26

Technical Analysis· Apr 8

Regulars· Sep 29

Newcomers· Sep 10